(MENAFN- Straits Research)
Cardiac Biomarkers Market Size & Growth Analysis
The global cardiac biomarkers market size was valued at USD 26.5 billion in 2025 and is projected to grow from USD 30.24 billion in 2026 to USD 86.86 billion by 2034, registering a CAGR of 14.1% during the forecast period from 2026 to 2034. North America dominated the cardiac biomarkers market with a market share of 39.2% in 2025.
Cardiac biomarkers are enzymes, proteins, and hormones released into the bloodstream during heart damage, helping to detect conditions such as myocardial infarction. The rising demand for point-of-care (POC) cardiac testing kits, valued for their fast and accurate results, is accelerating market growth. Technological integration, including AI and machine learning, enhances diagnostic precision, monitoring, and interpretation, further supporting adoption. Cardiac test kits with multi-parameter panels enable the rapid detection of abnormalities, reduce diagnostic delays, and enhance clinical decision-making in emergencies. Overall, fast diagnostics and advanced technologies continue to drive the market.
Cardiac Biomarkers Market Key Takeaways
Global Market Size & Growth
2025 Market Size: USD 26.5 Billion
2026 Market Size: USD 30.24 Billion
2034 Projected Market Size: USD 86.86 Billion
Forecast Period: 2026–2034
Base Year: 2025
Market CAGR (2026–2034): 14.1%
Regional Insights
Largest Regional Market (2025): North America
North America Market Share (2025): 39.2%
Fastest-Growing Region: Asia Pacific
Asia Pacific CAGR (2026–2034): 14.7%
Segment Insights
By Type
Leading Segment: Troponins (T and I)
Market Share in 2025: 48.7%
By Application
Fastest-Growing Segment: Congestive Heart Failure
CAGR: 13.5% (2026–2034)
By End-User
Leading Segment: Laboratory Testing
Market Share in 2025: 57.4%
Download a Free Sample To learn more about this report,
Cardiac Biomarkers Market Trends
Growing Adoption of High-Sensitivity Cardiac Biomarker Testing
The cardiac biomarkers market trends are being driven by the increasing prevalence of cardiovascular diseases, growing demand for early diagnosis, and advances in high-sensitivity diagnostic technologies. Cardiac biomarkers such as troponin, creatine kinase-MB (CK-MB), and natriuretic peptides are widely used to support the diagnosis and risk assessment of acute coronary syndromes, heart failure, and other cardiovascular conditions. High-sensitivity cardiac troponin assays are gaining greater adoption because they can detect very low concentrations of cardiac troponin and support earlier identification of myocardial injury. Healthcare providers are also increasingly integrating automated immunoassay platforms, point-of-care testing, and digital laboratory systems to accelerate turnaround times and improve clinical decision-making. In addition, growing use of biomarker testing for cardiovascular risk stratification and heart failure management is expanding the application of advanced diagnostic assays. Continued development of multiplex testing and improved analytical sensitivity is further supporting innovation in cardiac biomarker diagnostics.
Recent Instances and Facts
2025: Clinical laboratories expanded adoption of high-sensitivity cardiac troponin assays to support faster assessment of patients with suspected acute myocardial injury.
2025: Diagnostic companies continued developing automated and point-of-care cardiac biomarker testing systems to shorten turnaround times and improve access to cardiovascular diagnostics.
2026: Researchers continued advancing multiplex cardiac biomarker panels and high-sensitivity assays to improve cardiovascular risk assessment, heart failure monitoring, and early disease detection.
These developments indicate that high-sensitivity troponin testing, point-of-care diagnostics, automated immunoassays, multiplex biomarker panels, and cardiovascular risk assessment will remain the key cardiac biomarkers market trends, improving diagnostic accuracy, accelerating clinical decision-making, and driving long-term growth across the global cardiovascular diagnostics industry.
Cardiac Biomarkers Market Dynamics
Market Drivers
Rising Prevalence of Cardiovascular Diseases and Increasing Demand for Early Cardiac Diagnosis
The cardiac biomarkers market is expanding due to the increasing prevalence of cardiovascular diseases, including myocardial infarction, heart failure, and other cardiac conditions. Cardiac biomarkers such as troponins, creatine kinase-MB, natriuretic peptides, and other diagnostic markers support the early detection, risk assessment, and management of cardiovascular disorders. Growing aging populations, increasing awareness of heart health, rising healthcare expenditure, and advancements in diagnostic testing technologies are further accelerating demand. These developments are significantly contributing to cardiac biomarkers market growth as healthcare providers increasingly rely on rapid and accurate biomarkers for timely clinical decision-making.
In 2025, diagnostic companies expanded cardiac biomarker testing portfolios with high-sensitivity assays and automated platforms designed to improve the speed and accuracy of cardiovascular disease diagnosis.
Market Restraints
High Testing Costs and Variability in Biomarker Interpretation
The cardiac biomarkers market faces challenges due to the cost of advanced diagnostic analyzers, specialized reagents, and laboratory infrastructure. Differences in patient characteristics, underlying conditions, and testing methods can also affect biomarker concentrations and complicate clinical interpretation. In addition, limited access to advanced diagnostic facilities in developing regions can restrict the adoption of sophisticated cardiac biomarker testing technologies. Recent cardiac biomarkers market analysis indicates that cost considerations and the need for skilled interpretation remain important barriers to broader market penetration.
In 2025, healthcare laboratories increased investments in automated cardiac testing systems and standardized assay workflows to improve testing efficiency and reduce variability in biomarker measurement.
Market Opportunities
Expansion of High-Sensitivity Testing and Point-of-Care Cardiac Diagnostics
The cardiac biomarkers market is expected to benefit from increasing adoption of high-sensitivity cardiac troponin assays, point-of-care testing, multiplex biomarker platforms, and advanced diagnostic technologies. High-sensitivity assays can support earlier detection of myocardial injury and enable more efficient clinical decision-making. Growing demand for rapid testing in emergency departments, outpatient settings, and decentralized healthcare environments is also creating significant growth opportunities. These developments are expected to strengthen the cardiac biomarkers market size by expanding the use of rapid and sensitive cardiovascular diagnostic solutions.
In 2025, diagnostic technology providers expanded high-sensitivity cardiac biomarker testing and point-of-care platforms to support faster assessment of patients with suspected acute cardiovascular conditions.
Market Challenges
Ensuring Biomarker Accuracy, Standardization, and Clinical Reliability
The cardiac biomarkers market continues to face challenges related to assay standardization, analytical accuracy, clinical interpretation, and integration of test results into healthcare workflows. Manufacturers must ensure consistent performance across different testing platforms while healthcare professionals must interpret biomarker levels alongside symptoms, imaging findings, and other clinical information. Variations in testing protocols and reference ranges can also affect comparability between laboratories. According to recent cardiac biomarkers market reports, companies are investing in high-sensitivity assays, automated analyzers, standardized testing procedures, and advanced data interpretation technologies to improve diagnostic reliability and strengthen long-term market competitiveness.
In 2025, cardiac diagnostics companies increased investments in high-sensitivity assay technologies and automated testing platforms to improve analytical accuracy, standardization, and clinical reliability of cardiac biomarker testing.
Cardiac Biomarkers Market Segmentation
By Type
Troponins (T and I) Segment is Projected to Register the Fastest Growth at a CAGR of 13.2%
The troponins (T and I) segment is projected to register the fastest growth at a CAGR of 13.2% during 2026–2034. In 2025, the segment accounted for 48.7% of the global cardiac biomarkers market, with a value of USD 12.91 billion. Growth is driven by increasing demand for accurate cardiac assessment, widespread use of troponin testing in cardiovascular diagnostics, and growing adoption of sensitive biomarker-based testing methods.
Myocardial muscle creatine kinase (CK-MB) accounted for 21.3% of the market, with a value of USD 5.64 billion and a CAGR of 9.6%. Myoglobin represented 14.8%, with a value of USD 3.92 billion and a CAGR of 10.1%, while others accounted for 15.2%, with a value of USD 4.03 billion and a CAGR of 11.7%.
Request Customization to receive a tailored report.
By Application
Congestive Heart Failure Segment is Projected to Register the Fastest Growth at a CAGR of 13.5%
The congestive heart failure segment is projected to register the fastest growth at a CAGR of 13.5% during 2026–2034. In 2025, the segment accounted for 18.9% of the global cardiac biomarkers market, with a value of USD 5.01 billion. Growth is driven by increasing demand for biomarker-based assessment of cardiac function, rising need for early detection and monitoring of heart failure, and expanding use of cardiac biomarkers in clinical decision-making.
Myocardial infarction dominated the application segment with a 37.8% share and a value of USD 10.02 billion. The segment is projected to grow at a CAGR of 11.6%. Acute coronary syndrome accounted for 34.6% of the market, with a value of USD 9.17 billion and a CAGR of 12.4%, while others represented 8.7%, with a value of USD 2.31 billion and a CAGR of 9.8%.
By End-User
Point of Care Testing Segment is Projected to Register the Fastest Growth at a CAGR of 14.3%
The point of care testing segment is projected to register the fastest growth at a CAGR of 14.3% during 2026–2034. In 2025, the segment accounted for 35.8% of the global cardiac biomarkers market, with a value of USD 9.49 billion. Growth is driven by increasing demand for rapid diagnostic results, growing adoption of decentralized testing, and the need for timely cardiac assessment in acute and emergency care settings.
Laboratory testing dominated the end-user segment with a 57.4% share and a value of USD 15.21 billion. Its leading position is supported by established laboratory infrastructure, broad availability of biomarker testing, and continued use of centralized diagnostic workflows. The segment is projected to grow at a CAGR of 10.7% during 2026–2034.
Others accounted for 6.8% of the market, with a value of USD 1.80 billion and a CAGR of 9.5%.
Speak to an Analyst to discuss market opportunities.
Cardiac Biomarkers Market Regional Outlook
North America Cardiac Biomarkers Market Analysis
North America cardiac biomarkers market accounted for 39.2% of the global market, reaching USD 10.39 billion in 2025, and is projected to grow at a CAGR of 10.9% during the forecast period. The market is driven by increasing prevalence of cardiovascular diseases, growing demand for early and accurate cardiac diagnosis, rising healthcare expenditure, and increasing adoption of advanced diagnostic technologies. Expanding use of biomarkers for cardiovascular risk assessment and disease monitoring continues to support regional market growth.
US Cardiac Biomarkers Market Insights
The US market is supported by increasing cardiovascular disease burden, growing demand for rapid cardiac diagnostics, rising healthcare expenditure, and expanding adoption of advanced biomarker-based testing across hospitals and diagnostic laboratories.
Canada Cardiac Biomarkers Market Insights
Canada's market growth is driven by increasing cardiovascular disease awareness, growing demand for early cardiac diagnosis, expanding healthcare infrastructure, and rising adoption of advanced diagnostic testing technologies.
Unlock Regional Insights to access country-level data, & regional trends.
Europe Cardiac Biomarkers Market Analysis
Europe cardiac biomarkers market accounted for 28.1% of the global market, reaching USD 7.45 billion in 2025, and is projected to grow at a CAGR of 10.4% during the forecast period. Increasing prevalence of cardiovascular diseases, growing demand for early diagnosis, rising healthcare investments, and expanding adoption of advanced diagnostic technologies continue to strengthen regional market growth. Increasing focus on preventive cardiovascular care and disease monitoring further supports market expansion.
UK Cardiac Biomarkers Market Insights
The UK market is supported by increasing cardiovascular disease management needs, growing demand for rapid diagnostic testing, rising healthcare investments, and expanding adoption of cardiac biomarker testing in hospitals and diagnostic facilities.
Germany Cardiac Biomarkers Market Insights
Germany market growth is driven by increasing cardiovascular disease prevalence, growing demand for advanced diagnostic solutions, rising healthcare expenditure, and expanding adoption of biomarker-based cardiac testing technologies.
Asia Pacific Cardiac Biomarkers Market Analysis
Asia Pacific cardiac biomarkers market accounted for 22.4% of the global market, reaching USD 5.94 billion in 2025, and is projected to grow at a CAGR of 14.7% during the forecast period. Rising prevalence of cardiovascular diseases, expanding healthcare infrastructure, increasing healthcare expenditure, and growing demand for early and accurate cardiac diagnosis continue to accelerate regional market growth. Increasing adoption of advanced diagnostic technologies and improving access to cardiovascular care further strengthen market expansion.
China Cardiac Biomarkers Market Insights
China's market is supported by increasing cardiovascular disease burden, expanding healthcare infrastructure, rising healthcare expenditure, growing demand for early diagnosis, and increasing adoption of advanced cardiac diagnostic technologies.
Japan Cardiac Biomarkers Market Insights
Japan's market growth is driven by an aging population, increasing demand for cardiovascular disease management, growing adoption of advanced diagnostic technologies, and rising use of cardiac biomarker testing for early detection and monitoring.
Middle East and Africa Cardiac Biomarkers Market Analysis
Middle East and Africa cardiac biomarkers market accounted for 4.2% of the global market, totaling USD 1.11 billion in 2025, and is projected to grow at a CAGR of 11.5% during the forecast period. Increasing prevalence of cardiovascular diseases, growing healthcare infrastructure investments, rising awareness of early cardiac diagnosis, and expanding adoption of advanced diagnostic technologies continue to support regional market growth.
UAE Cardiac Biomarkers Market Insights
The UAE market is supported by increasing investments in advanced healthcare infrastructure, growing cardiovascular disease management needs, rising demand for early diagnostic testing, and expanding adoption of advanced cardiac biomarker technologies.
Africa Cardiac Biomarkers Market Insights
Africa's market growth is supported by increasing cardiovascular disease awareness, expanding healthcare infrastructure, growing access to diagnostic services, and rising adoption of affordable and advanced cardiac testing technologies, creating long-term opportunities for cardiac biomarkers across the region.
Cardiac Biomarkers Market Competitive Landscape
The global cardiac biomarkers market is moderately consolidated, with leading diagnostics, healthcare, and life sciences companies competing through continuous product innovation, strategic partnerships, advanced immunoassay technologies, and investments in cardiovascular diagnostic solutions. The major players in the market include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Ortho Clinical Diagnostics, Beckman Coulter (Danaher Corporation), Thermo Fisher Scientific, BioMérieux, SeraCare Life Sciences, Randox Laboratories, and Quidel Corporation.
Industry participants are increasingly focusing on developing high-sensitivity cardiac biomarker assays, automated immunoassay platforms, point-of-care testing solutions, and multiplex diagnostic technologies to support the early detection and risk assessment of cardiovascular conditions. Companies are also investing in advanced troponin testing, biomarker standardization, laboratory automation, rapid testing platforms, and digital diagnostic technologies while expanding collaborations with hospitals, clinical laboratories, and healthcare providers to improve diagnostic accuracy and enable faster clinical decision-making.
ACS Biomarker B.V.: An Emerging Market Player
ACS Biomarker B.V. has emerged as a prominent player in the cardiac biomarkers market through its focus on biomarker research, assay development, and diagnostic solutions designed to support cardiovascular disease assessment. The company continues to strengthen its market presence by developing specialized biomarker technologies and analytical solutions that support research and clinical applications in cardiovascular health.
In 2025, ACS Biomarker B.V. continued to advance its biomarker development and analytical capabilities for cardiovascular applications, supporting improved biomarker-based disease assessment and further strengthening its position in the global cardiac biomarkers market.
List of Key and Emerging Players in Cardiac Biomarkers Market
Roche Diagnostics
Abbott Laboratories
Siemens Healthineers
Ortho Clinical Diagnostics
Beckman Coulter (Danaher Corporation)
Thermo Fisher Scientific
BioMérieux
SeraCare Life Sciences
Randox Laboratories
Quidel Corporation
Hoffmann-La Roche AG
Hologic, Inc.
Johnson & Johnson Services Inc.
Trivitron Healthcare
ACS Biomarker B.V.
Novartis AG
Key Industry Developments
March 2026: Medtronic expanded its mechanical ventilation portfolio with advanced ventilator systems designed for intensive care units and respiratory care settings, incorporating improved monitoring capabilities and patient management features.
January 2026: Getinge expanded its respiratory care solutions portfolio with next-generation mechanical ventilators designed for critical care applications, focusing on enhanced ventilation performance, workflow efficiency, and patient safety.
October 2025: Dräger expanded its ventilator portfolio with advanced mechanical ventilation technologies featuring improved respiratory monitoring, automation capabilities, and solutions for intensive care and emergency care environments.
August 2025: Hamilton Medical expanded its mechanical ventilation solutions with upgraded ICU ventilators incorporating intelligent ventilation modes and advanced respiratory monitoring technologies to support personalized patient care.
Report Scope
Comments
No comment